# GLP-1 Cost and Insurance Coverage in 2026: Ozempic, Wegovy, Mounjaro, Zepbound > **Summary:** What GLP-1 weight loss medications actually cost in 2026, what insurance covers, manufacturer savings programs, compound vs brand pricing, and how telehealth changes the math. > **Publisher:** WeightFAQ > **Author:** WeightFAQ Staff > **Published:** 2026-06-04 > **Updated:** 2026-06-04 > **Canonical URL:** https://weightfaq.com/weight-loss/glp-1-cost-insurance/ > **Content type:** Evergreen guide > **Tags:** glp-1, ozempic, wegovy, mounjaro, zepbound, cost, insurance > **Image:** https://weightfaq.com/_astro/glp-1-cost-insurance-hero.BEmBnjYG.webp — Injectable GLP-1 medication pen beside insurance paperwork and a calculator ## Quick answer In 2026, U.S. cash list prices for the four major GLP-1 brands sit in a tight band: **Ozempic ~$950–$1,100/month**, **Wegovy ~$1,350/month**, **Mounjaro ~$1,070/month**, and **Zepbound ~$1,060/month** for the auto-injector pen. With commercial insurance coverage, out-of-pocket costs typically run **$0–$200/month** when a plan covers the drug and you use a manufacturer savings card; with no coverage, expect close to the full cash price. **Eli Lilly's LillyDirect self-pay program for Zepbound vials** is the most-discussed cash-pay route this cycle, priced around **$349–$549/month** depending on dose. Cost is the single biggest barrier to starting a GLP-1 in 2026, and the price you pay depends much more on coverage and program eligibility than on the brand itself. This article walks through cash prices, insurance rules in the U.S. and UK, manufacturer savings programs, compounding, telehealth bundles, and a practical checklist for finding out what you will actually pay. ## Who this is for This article is for adults considering a GLP-1 weight-loss medication — Ozempic, Wegovy, Mounjaro, or Zepbound — who want a clear cost picture before a clinician visit. Prices are typical 2026-Q2 figures and will move; confirm specific numbers with your insurer, clinician, or manufacturer. For a clinical comparison of the drugs themselves, see the [GLP-1 medications compared](https://weightfaq.com/weight-loss/glp-1-medications-compared/) hub. ## Cash price by medication The table below collects typical 2026-Q2 U.S. cash list prices for a one-month supply at standard maintenance doses. List prices are what a pharmacy would charge without insurance discounts or manufacturer coupons, and they change without notice. | Medication | Manufacturer | FDA-approved indication | Typical U.S. cash list price/month | Notes | | --- | --- | --- | ---: | --- | | Ozempic | Novo Nordisk | Type 2 diabetes | $950–$1,100 | Frequently prescribed off-label for weight loss | | Wegovy | Novo Nordisk | Chronic weight management; cardiovascular risk reduction in eligible adults | $1,350 | FDA-approved for obesity at 2.4 mg/wk | | Mounjaro | Eli Lilly | Type 2 diabetes | $1,070 | Sometimes prescribed off-label for weight loss | | Zepbound (pen) | Eli Lilly | Chronic weight management; moderate-to-severe OSA in adults with obesity | $1,060 | FDA-approved for obesity at 5–15 mg/wk | | Zepbound vials (LillyDirect) | Eli Lilly | Chronic weight management | $349–$549 | Self-pay only; does not stack with insurance | | Saxenda | Novo Nordisk | Chronic weight management | $1,349 | Daily injection; NovoCare cash-pay ~$530/month | | Generic liraglutide 3.0 mg | Teva (and others) | Chronic weight management | Launch pricing 2024+ | First generic GLP-1 for obesity; approved Aug 2024 | Two takeaways: cash prices for the auto-injector pens cluster around **$1,000–$1,350/month**, and **the LillyDirect Zepbound vial program is the only major brand-name route well below that band**. Novo Nordisk has at times offered a Wegovy cash-pay program with a meaningful discount; check the manufacturer site for current eligibility and pricing. For a payer-by-payer decision matrix specifically on the two obesity-indication brands — including which brand wins under commercial insurance, cash-pay, Medicare with OSA, and Medicare with CVD — see [Wegovy vs Zepbound](https://weightfaq.com/weight-loss/wegovy-vs-zepbound/). **Daily-vs-weekly cost.** Saxenda (liraglutide 3.0 mg) is dosed once daily and carries essentially the same brand list price as weekly Wegovy (~$1,349/month), and its NovoCare cash-pay route (~$530/month) sits close to Wegovy's ($499/month for eligible patients). The larger 2026 shift is on the generic side: liraglutide's US patent expired in December 2023 and the FDA approved the first generic liraglutide 3.0 mg from Teva in August 2024, so a daily-injection GLP-1 for obesity is now available at a cash-pay price meaningfully below any branded weekly agent — launch pricing is still settling. For the full daily-vs-weekly walkthrough with STEP-8 head-to-head numbers, adolescent trial data, and when Saxenda still makes sense, see [Saxenda vs Wegovy](https://weightfaq.com/weight-loss/saxenda-vs-wegovy/). ## What insurance actually covers in 2026 Coverage varies dramatically by plan, and "GLP-1 coverage" is not a single yes/no question — it depends on the indication, your BMI, prior authorization criteria, and the specific drug your prescriber writes. ### U.S. commercial insurance Roughly **30–40% of U.S. commercial plans** cover Wegovy or Zepbound for chronic weight management in 2026. Plans that do cover weight-loss GLP-1s almost always require **prior authorization** (documented BMI ≥30, or BMI ≥27 plus a weight-related condition), **documented prior weight-loss attempts**, and sometimes **step therapy**. For the **type 2 diabetes** indication, coverage of Ozempic and Mounjaro is much wider, typically with a $25–$100/month copay after deductible. If your plan covers a weight-loss GLP-1, expect a typical out-of-pocket cost of **$25–$200/month**, dropping to **$0–$50/month** with a manufacturer savings card stacked on top until the card's annual cap is reached. ### Medicare **Medicare Part D does not cover GLP-1 medications for obesity alone.** Section 1860D-2(e)(2)(A) of the Social Security Act excludes drugs used for weight loss from Part D coverage, and that exclusion is still in force in 2026. However, Part D **does** cover: - **Ozempic and Mounjaro** when prescribed for type 2 diabetes. This Part D pathway is the single biggest structural reason patients with T2D plus obesity end up on Ozempic or Mounjaro rather than Wegovy or Zepbound — for the head-to-head decision between those two T2D-labeled brands, see [Ozempic vs Mounjaro](https://weightfaq.com/weight-loss/ozempic-vs-mounjaro/). - **Wegovy (semaglutide 2.4 mg)** when prescribed for **cardiovascular risk reduction** in eligible adults with established cardiovascular disease and obesity or overweight. CMS clarified Part D coverage for this indication after the FDA expanded Wegovy's label in 2024. Medicare Advantage and Part D plans set their own copays and prior authorization rules within these limits. If you are on Medicare and the only indication is weight management, expect to pay the cash price. ### Medicaid Medicaid coverage of GLP-1s for obesity is **state-by-state**. As of 2026, roughly 15 state Medicaid programs cover at least one branded GLP-1 for chronic weight management, usually with criteria similar to commercial plans plus stricter documentation requirements. All state Medicaid programs cover GLP-1s for type 2 diabetes when medically appropriate. ### UK (NHS and private) In the UK, **Wegovy and Mounjaro are available through NHS specialist weight management services** with strict eligibility — typically BMI ≥35 with a weight-related condition, treatment limited to a maximum duration set by NICE guidance, and access gated through tier-3 or tier-4 weight management clinics. Waiting lists for these services have been long. Through **private UK clinics**, cash prices for Wegovy or Mounjaro typically run **£150–£250 per month** for the medication itself, plus a clinic or membership fee on top. These figures are meaningfully lower than U.S. cash prices because of UK reference pricing and a more constrained licensed-clinic distribution model. ## Manufacturer savings programs Both Novo Nordisk and Eli Lilly run patient assistance programs that can substantially lower the monthly cost for eligible patients. The fine print matters — most programs exclude patients with government insurance (Medicare, Medicaid, Tricare) and require commercial coverage or full cash-pay status. ### Novo Nordisk — Wegovy and Ozempic savings cards Commercially insured patients whose plan **covers Wegovy** may pay as little as **$0–$25/month** with the savings card, subject to monthly and annual caps. Commercially insured patients whose plan **does not cover Wegovy** have at times been eligible for a cash-pay savings program cutting roughly $500–$650 off the monthly price. Ozempic also has a savings card for diabetes patients on commercial coverage, typically pricing the drug at **$25/month**. ### Eli Lilly — Zepbound savings card and LillyDirect vials Commercially insured patients whose plan **covers Zepbound** may pay as little as **$25/month** with the Zepbound savings card. For patients without coverage, **LillyDirect** offers Zepbound single-dose vials at roughly **$349/month** for 2.5 mg, **$499/month** for 5 mg, and **$549/month** for higher doses. LillyDirect requires a U.S. clinician prescription, ships through a partner pharmacy, and does not stack with insurance or the Zepbound savings card. The program covers Zepbound only — Mounjaro (the same tirzepatide molecule under the T2D label) has no equivalent direct-to-consumer vial route in 2026, which is one of the practical reasons Zepbound is the cheaper cash-pay tirzepatide brand; see [Mounjaro vs Zepbound](https://weightfaq.com/weight-loss/mounjaro-vs-zepbound/) for the coverage-vs-cash-pay decision walk-through. Eligibility for all manufacturer programs changes — confirm current terms on the program site before relying on a specific figure. ## Compounded GLP-1s: cheaper, riskier, and now legally constrained During the 2022–2024 semaglutide and tirzepatide shortages, compounding pharmacies legally produced large volumes of non-branded GLP-1 preparations under FDA shortage rules. Compounded prices commonly ran **$200–$400/month**, and a large telehealth ecosystem grew up around them. That landscape changed in **mid-2024**, when the FDA determined that semaglutide and tirzepatide were **no longer in shortage**, ending the broad legal basis for routine compounding. FDA safety communications since then have cited dosing errors, incorrect salt forms of semaglutide, sterility problems at some facilities, and marketing by non-licensed online sellers. With LillyDirect Zepbound vials now priced in the same band as compounded semaglutide used to be, **the price gap that drove the compounded market has largely closed**. The safer 2026 path is a licensed-clinician prescription plus LillyDirect (for Zepbound) or a manufacturer savings card (for Wegovy). For patients still weighing sub-labeled compounded doses — for example, [microdosing for cost reduction](https://weightfaq.com/weight-loss/glp-1-microdosing/) at $99–$200/month for compounded semaglutide — our microdosing guide covers the proportional efficacy trade-off (less weight loss than labeled doses), the 2026 503A legal picture, and when sub-labeled dosing is a reasonable bridge versus a weaker alternative to the labeled product. See [weight loss drug safety](https://weightfaq.com/weight-loss/weight-loss-drug-safety/) for the class-wide picture. ## Telehealth pricing models Telehealth weight-loss programs are the most common route to a GLP-1 prescription for cash-pay patients in 2026. Pricing falls into three common models: - **Membership + medication, billed separately.** A monthly fee of **$99–$199** covers clinician visits, messaging, and coaching; medication is billed at the pharmacy (often paired with a manufacturer savings card). - **Bundled membership + LillyDirect Zepbound vials.** A flat clinical-service fee with a separate bill for the vials. - **All-in-one cash-pay programs.** A single monthly fee — commonly **$199–$349** — that includes clinician visits, coaching, and the medication. Before signing up: verify the medication source (state-licensed U.S. pharmacy, FDA-approved branded products, or LillyDirect vials); check whether the advertised price includes the drug or only the membership; read the cancellation terms. See [telehealth weight loss](https://weightfaq.com/weight-loss/telehealth-weight-loss/) for the broader landscape. ## Cost over a 12-month course GLP-1 weight-loss treatment is typically a **long-term commitment** — most published trials show that stopping the drug leads to substantial regain within a year. A realistic budget should look at 12-month and 24-month totals rather than a single monthly figure. | Scenario | Effective monthly cost | 12-month total | | --- | ---: | ---: | | U.S. commercial insurance with coverage + manufacturer savings card | $0–$50 | $0–$600 | | LillyDirect Zepbound vials (self-pay) | $349–$549 | $4,200–$6,600 | | U.S. cash-pay branded pen, no insurance, no savings card | $1,000–$1,400 | $12,000–$16,800 | | NHS via specialist weight management service (UK) | £0 (eligibility-gated) | £0 | | UK private clinic | £150–£250 | £1,800–£3,000 | These totals do not include clinician visits, labs, or telehealth membership fees, which can add **$100–$2,000/year** depending on the model. ## Cost vs effect: is it worth it? **GLP-1 cost-effectiveness flips depending on coverage.** At a covered-plus-savings-card cost of $0–$50/month, a GLP-1 is one of the highest-leverage interventions available for chronic obesity. At cash-pay $1,000+/month over 2–3 years, total cost of ownership approaches the upfront price of bariatric surgery — and the surgery produces more durable weight loss without an ongoing prescription. For a structured side-by-side, see [bariatric surgery vs GLP-1 medications](https://weightfaq.com/weight-loss/bariatric-surgery-vs-glp-1-medications/) and [bariatric surgery cost and insurance](https://weightfaq.com/weight-loss/bariatric-surgery-cost-insurance/). ## What if my coverage drops? If your plan stops covering Wegovy or Zepbound mid-treatment — a common scenario when employers update formularies or prior authorizations expire — do not stop cold without a plan. The STEP-1 extension showed roughly two-thirds of lost weight returning within 12 months of an unsupported stop. A 16- to 32-week taper, a switch to LillyDirect Zepbound vials ($349–$549/month) while you appeal coverage, or an off-label lower-dose maintenance prescription are all viable bridges. If the appeal fails and the pharmacy handoff pushes you from one GLP-1 to another, [how to switch between GLP-1 medications](https://weightfaq.com/weight-loss/switching-glp-1-medications/) walks through the mechanics — no washout, restart at the lowest step of the new drug, expect 4 to 6 weeks of GI adjustment — so the forced move does not become a scale rebound. The full taper-vs-stop-vs-maintenance-dose comparison, the five levers that reduce regain, and when to involve your endocrinologist (especially if you have type 2 diabetes) are covered in our guide to [rebound weight gain after stopping GLP-1](https://weightfaq.com/weight-loss/rebound-weight-gain-after-stopping-glp-1/). ## How to actually find out what you will pay A practical 4-step checklist before your first GLP-1 prescription: 1. **Check your formulary.** Log into your insurance member portal and search for Wegovy, Zepbound, Ozempic, and Mounjaro. Note the tier, copay, and any prior authorization or step therapy flags. If your plan is through an employer, the HR or benefits team can confirm whether the employer added a weight-management drug exclusion to the underlying carrier policy. 2. **Call the insurer.** Ask specifically: "Is Wegovy [or Zepbound] covered under my plan, and what are the prior authorization criteria?" Ask for the criteria in writing if possible. Have your member ID and prescription benefit information ready. 3. **Confirm savings card eligibility.** Visit the Wegovy or Zepbound manufacturer site, enter your insurance status, and confirm the savings-card amount and monthly cap before your clinician visit. The savings card is usually issued before your first fill. 4. **Compare LillyDirect Zepbound vials** if you have no coverage or your prior authorization is denied. LillyDirect requires a U.S. clinician prescription; ask your prescriber whether they can route through LillyDirect if branded pen coverage falls through. This 30-minute exercise produces a realistic monthly out-of-pocket figure and almost always reveals at least one cost-reducing path the clinic itself would not bring up. If your only affordable route ends up being a cash-pay virtual clinic, walk through the 10-point [telehealth weight-loss provider checklist](https://weightfaq.com/weight-loss/telehealth-weight-loss/) before signing up so you catch cancellation and prior-authorization gaps early. ## Common mistakes - **Assuming insurance covers it.** Coverage for branded weight-loss GLP-1s is still the minority case among U.S. commercial plans. Don't assume; check. - **Signing up for telehealth before checking coverage.** Some telehealth programs do not bill insurance at all, even when your plan would cover the same drug at the pharmacy. Check coverage first; pick the lowest-cost route second. - **Buying from non-licensed online sellers.** Compounded or unbranded GLP-1s from offshore or unlicensed sites carry meaningful safety risk. Use a U.S. state-licensed pharmacy and a clinician-issued prescription. - **Ignoring the dose-escalation cost ramp.** All GLP-1s use a slow dose titration that takes 4–5 months to reach the maintenance dose. Some plans cover the starting dose differently from the maintenance dose; ask before you commit. - **Forgetting that this is a long-term cost.** Treat the monthly cost as a 24- to 36-month commitment when budgeting, not a single course. ## Frequently asked questions **How much does Ozempic cost without insurance?** Ozempic's U.S. list price in 2026 is roughly $950–$1,100 per month for a one-month supply of weekly pens. Because Ozempic is FDA-approved for type 2 diabetes (not weight loss), most insurance plans cover it only when prescribed for diabetes. If you do not have diabetes and your clinician prescribes Ozempic off-label for weight loss, expect to pay close to the full cash price unless you qualify for a manufacturer savings program. **Does insurance cover Wegovy for weight loss?** Coverage is mixed in 2026. Roughly 30–40% of U.S. commercial plans cover Wegovy or Zepbound for chronic weight management when criteria are met — typically BMI ≥30, or BMI ≥27 with a weight-related condition. Plans that cover Wegovy almost always require prior authorization and documented prior weight-loss attempts. Medicare Part D still excludes weight-loss-only drugs by statute, but covers semaglutide-based drugs for diabetes and for cardiovascular risk reduction in eligible adults. **What is the cheapest GLP-1 for weight loss?** As of 2026, the lowest-cost branded route for weight loss is the LillyDirect self-pay program for Zepbound vials, which sits around $349–$549 per month depending on dose. That is materially less than the auto-injector pen cash price (~$1,060/month). For people with commercial insurance, a covered prescription plus the Wegovy or Zepbound manufacturer savings card can bring monthly costs to $0–$50. **Are compounded GLP-1s safe?** Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA has issued safety warnings about dosing errors, incorrect salt forms, and sterility problems with some compounded versions. After the FDA's 2024 determination that semaglutide and tirzepatide are no longer in shortage, the legal scope for compounding narrowed materially. If cost is the barrier, manufacturer self-pay programs (such as LillyDirect Zepbound vials) and the Wegovy savings card are usually safer and now often comparable in price. **Does Medicare cover Ozempic or Wegovy?** Medicare Part D covers Ozempic for type 2 diabetes and covers semaglutide (Wegovy) for cardiovascular risk reduction in eligible adults with established cardiovascular disease and obesity or overweight. Medicare does not cover GLP-1s prescribed solely for weight loss, because Part D excludes weight-loss drugs by statute. If you are on Medicare and the only indication is weight management, expect to pay the full cash price. **How much is Zepbound on LillyDirect?** Eli Lilly's LillyDirect self-pay program for Zepbound vials prices the lower doses at around $349 per month (2.5 mg) and higher doses up to roughly $549 per month (typically 10 mg), with the schedule periodically updated. LillyDirect is a cash-pay option intended for adults without insurance coverage for Zepbound; it does not stack with insurance or the Zepbound savings card. **How much does Wegovy cost in the UK?** On the NHS, Wegovy and Mounjaro are available without out-of-pocket prescription cost through specialist weight management services in England (eligibility is strict — typically BMI ≥35 plus a weight-related condition, and waiting lists can be long). Through private clinics in the UK, cash prices for Wegovy or Mounjaro typically run £150–£250 per month for the medication, plus a clinic or membership fee.

Sources